Cohance Lifesciences · NSE: COHANCE · BSE: 543064
Q3 FY25 results · Oct–Dec 2024
Cohance Lifesciences reported revenue from operations of ₹307.15 crore (up 39.7% from Q3 FY24) and net profit of ₹83.29 crore (up 78.1% from Q3 FY24) for Q3 FY25 (Oct–Dec 2024), on a consolidated basis.
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 307.15 | 219.82 | +39.7% | 257.72 | +19.2% |
| Other income | 15.71 | 14.34 | +9.5% | 14.12 | +11.3% |
| Total income | 322.86 | 234.16 | +37.9% | 271.84 | +18.8% |
| Profit before tax | 109.73 | 65.47 | +67.6% | 99.50 | +10.3% |
| Net profit for the period | 83.29 | 46.75 | +78.1% | 81.98 | +1.6% |
| Attributable to shareholders of the company | 82.88 | — | — | 82.21 | +0.8% |
| EPS, basic (₹) | 3.26 | 1.84 | +77.0% | 3.23 | +0.8% |
| Net margin (%) | 27.1 | 21.3 | 31.8 |
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 275.39 | 212.83 | +29.4% | 236.06 | +16.7% |
| Other income | 15.18 | 13.97 | +8.7% | 13.43 | +13.0% |
| Total income | 290.57 | 226.79 | +28.1% | 249.49 | +16.5% |
| Profit before tax | 114.60 | 69.50 | +64.9% | 100.68 | +13.8% |
| Net profit for the period | 86.35 | 52.36 | +64.9% | 76.33 | +13.1% |
| EPS, basic (₹) | 3.39 | 2.06 | +64.7% | 3.00 | +13.1% |
| Net margin (%) | 31.4 | 24.6 | 32.3 |
Consolidated
- Filed with BSE
- 13 Feb 2025, 16:05 IST
- Board meeting
- 12 Feb 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 13 Feb 2025, 16:05 IST
- Board meeting
- 12 Feb 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE